&nbsp;

MucinousOvarianCancerTreatmentPathwayMap_2020-01.pdf

Mar 2020

Regimen

MPC+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

ODB - General Benefit

procarbazine

Drugs Used:

riTUXimab (Unfunded),

Quick Link(s):

Regimen Monograph

Dec 2020

Regimen

MFOLFOX6+TRAS

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Manipulation sécuritaire des médicaments contre le cancer et des fluides corporels à la maison

Guidelines and Advice

Virtual Care in Patients with Cancer: A Systematic Review

Status: Current
ID: ES 30-1

Mar 2021

Document

metis-brochure-thumbnail.jpg

Apr 2021

Document

metis-fr-brochure-thumbnail.jpg

May 2021

Regimen

VENE(MNT)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

venetoclax - In Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia, based on criteria

Exceptional Access Program

venetoclax - In Combination with Rituximab - Relapsed Chronic Lymphocytic Leukemia, based on criteria

Drugs Used:

venetoclax

... Show more tags

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

MFOLFOX6+NIVL

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - First-line Treatment of Advanced Gastric, Esophageal, and Esophagogastric Junction Adenocarcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2023

Measuring Ontario’s Small Area Inequalities in Cancer (MOSAIC) Study

Document